Entering text into the input field will update the search result below

Astellas Pharma agrees to buy Iveric Bio for $5.9 billion

Apr. 30, 2023 9:24 PM ETIVERIC bio, Inc. (ISEE), ALPMF, ALPMYAPLSBy: Joshua Fineman, SA News Editor1 Comment
Macro photos of the human eye - cataract clouding of the lens, deterioration of vision. Treatment, surgery and ophthalmology

Zarina Lukash/iStock via Getty Images

Astellas Pharma Inc. (OTCPK:ALPMF) agreed to acquire Iveric Bio (NASDAQ:ISEE) for $5.9 billion to add ophthalmology capabilities to the Japanese pharmaceutical giant.

Under the agreement, Astellas (OTCPK:ALPMF) agreed to purchase Iveric Bio (ISEE) for $40 a share, representing a 22% premium to

Recommended For You

Comments (1)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

AMP Biotech Research profile picture
Q2 biopharma M&A bonanza continues.

Last month:
BLU to be acquired by $GSK for ~$2B (103% premium)
RXDX to be acquired by $MRK for ~$11B (75% premium)

Interesting that $ISEE = one of the most widely held stocks by the 36 biopharma hedge funds in our BiopharmIQ tracker (15/36)

$BLU (8/36) and $RXDX (10/36) were some of the most widely held stocks by biopharma hedge funds too.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.